The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications.
Level 5 - mechanism / opinion, no new human data
Narrative review of animal and human publications without systematic search methodology
PubMed 14695925 · doi:10.1002/biof.5520180212
What was done
This was a narrative review examining animal and human publications regarding the impact of HMG-CoA reductase inhibitors (statins) on coenzyme Q10 (CoQ10) levels and cardiac function.
What was found
The abstract reports no quantitative data, sample sizes, or effect estimates. It asserts that statin therapy causes dose-dependent CoQ10 depletion associated with adverse cardiac outcomes in animal and human studies, particularly in older adults and individuals with heart failure, and states that CoQ10 supplementation prevents deficiency without attenuating statin efficacy.
Why it matters
This paper highlights clinical concerns regarding statin-induced CoQ10 depletion and advocates for co-administration of CoQ10 in patients receiving statin therapy.
Limits
No primary data, numerical outcomes, search criteria, or study counts are provided in the abstract. As a narrative review rather than a systematic synthesis, it is prone to selection bias and reflects expert opinion.
Cited by
- supports Statin medications block and deplete coenzyme Q10 in the body.